1 / 3

A novel replication-competent modified vaccinia Tiantan (MVTT)-based HIV Vaccine

A novel replication-competent modified vaccinia Tiantan (MVTT)-based HIV Vaccine Haibo Wang 1, 2 , Linqi Zhang 3 and Zhiwei Chen 1 1 AIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, PR. China;

brittany-harrell
Download Presentation

A novel replication-competent modified vaccinia Tiantan (MVTT)-based HIV Vaccine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A novel replication-competent modified vaccinia Tiantan (MVTT)-based HIV Vaccine Haibo Wang1, 2, Linqi Zhang3 and Zhiwei Chen1 1 AIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, PR. China; 2 Zhuhai International Travel Healthcare Center, Zhuhai, 519020, PR China; 3 Comprehensive AIDS Research Center and Research Center for Public Health, School of Medicine, Tsinghua University, Beijing, 100084, PR China Advantages of MVTT: Patented live replicating viral vector(Virology 2005); Immunogenic than MVA (PLoS One 2009); Highly attenuated and safe in SCID mice(Vaccine 2010); Protective immunity(JVI 2013). Problems: Instability of foreign genes; Screening process.

  2. In vitro characterization p3F p2F p4F p1F A D gag-pol env p1R p2R p4R p3R 1 2 3 4 5 6 7 8 9 10 11 12 13 14 E Template: 1,4,8,12 MVTTHKU-gpe/AE13; 2,5,9,13 MVTT; 3,6,10,14 Blank. Lane 1-3: primer set 1, indicating the large deletion site on the genome. Lane 4-6: primer set 2, indicating the insertion of env. Lane 8-10: primer set 3, indicating the insertion of gag. Lane 12-14: primer set 4, indicating the insertion of pol. B C MVTT M MVTTHKU-gpe/AE13 Gag-pol P1 Env P6 Pol Gag MVTT MVTTHKU-gpe/AE13

  3. In vivo characterization A B Conclusion • We have constructed a novel MVTT-based HIV vaccine to express env and gag-pol genes of HIVCRF01_AE. • This vaccine remainsreplication-competentwith excellent transgene stability. • The vaccine displays satisfactory safety and immunogenicity profiles in small animals. • Non-human primates studies and human trials have been planned to further characterize its immunogenicity. • Given the success (although modest) of RV144 trial, we believe this novel replication-competent modified vaccinia Tiantan-based vaccine will play a key role during the combating of HIV/AIDS pandemic. We thank HK-RGC762811, HKU-UDF and China’s Mega Project 2012ZX10001-009 for support.

More Related